N-n-Butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice.
Animals
Carbon Tetrachloride
/ administration & dosage
Dose-Response Relationship, Drug
Haloperidol
/ administration & dosage
Hepatic Stellate Cells
/ drug effects
Injections, Intraperitoneal
Liver Cirrhosis
/ chemically induced
Male
Mice
Mice, Inbred C57BL
Molecular Structure
Structure-Activity Relationship
Thioacetamide
/ administration & dosage
Transforming Growth Factor beta1
/ antagonists & inhibitors
N-n-butyl haloperidol iodide
TGF-β signaling
TGFBR2
antifibrotic
c-Jun
human hepatic stellate cell line LX-2
liver fibrosis
Journal
Acta pharmacologica Sinica
ISSN: 1745-7254
Titre abrégé: Acta Pharmacol Sin
Pays: United States
ID NLM: 100956087
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
05
08
2020
accepted:
17
02
2021
pubmed:
25
3
2021
medline:
19
3
2022
entrez:
24
3
2021
Statut:
ppublish
Résumé
N-n-Butyl haloperidol iodide (F
Identifiants
pubmed: 33758354
doi: 10.1038/s41401-021-00630-7
pii: 10.1038/s41401-021-00630-7
pmc: PMC8724321
doi:
Substances chimiques
N-n-butyl haloperidol iodide
0
Tgfb1 protein, mouse
0
Transforming Growth Factor beta1
0
Thioacetamide
075T165X8M
Carbon Tetrachloride
CL2T97X0V0
Haloperidol
J6292F8L3D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-145Informations de copyright
© 2021. The Author(s), under exclusive licence to CPS and SIMM.
Références
Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
pubmed: 21497738
pmcid: 3079877
doi: 10.1016/j.bpg.2011.02.005
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–18.
pubmed: 15690074
pmcid: 546435
doi: 10.1172/JCI24282
Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397–411.
pubmed: 28487545
doi: 10.1038/nrgastro.2017.38
Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64:830–41.
pubmed: 25681399
doi: 10.1136/gutjnl-2014-306842
Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180–90.
pubmed: 27646933
doi: 10.1136/gutjnl-2016-312431
Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
pmcid: 7226751
doi: 10.3390/cells9040875
Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:S15–24.
pubmed: 25920084
doi: 10.1016/j.jhep.2015.02.039
Huang ZQ, Shi GG, Zheng JH, Liu B. Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium current. Acta Pharmacol Sin. 2003;24:757–63.
pubmed: 12904274
Gao FF, Shi GG, Zheng JH, Liu B. Protective effects of N-n-butyl haloperidol iodide on myocardial ischemia-reperfusion injury in rabbits. Chin J Physiol. 2004;47:61–6.
pubmed: 15481787
Wang JZ, Cai CY, Zhang YM, Zheng JH, Chen YC, Li WQ, et al. N-n-Butyl haloperidol iodide protects against hypoxia/reoxygenation-induced cardiomyocyte injury by modulating protein kinase C activity. Biochem Pharmacol. 2010;79:1428–36.
pubmed: 20105432
doi: 10.1016/j.bcp.2010.01.021
Zhang Y, Chen G, Zhong S, Zheng F, Gao F, Chen Y, et al. N-n-butyl haloperidol iodide ameliorates cardiomyocytes hypoxia/reoxygenation injury by extracellular calcium-dependent and -independent mechanisms. Oxid Med Cell Longev. 2013;2013:912310.
pubmed: 24392181
pmcid: 3857550
doi: 10.1155/2013/912310
Zhang Y, Liao H, Zhong S, Gao F, Chen Y, Huang Z, et al. Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation. Sci Rep. 2015;5:11809.
pubmed: 26134032
pmcid: 4488875
doi: 10.1038/srep11809
Lu S, Zhang Y, Zhong S, Gao F, Chen Y, Li W, et al. N-n-butyl haloperidol iodide protects against hypoxia/reoxygenation injury in cardiac microvascular endothelial cells by regulating the ROS/MAPK/Egr-1 Pathway. Front Pharmacol. 2016;7:520.
pubmed: 28111550
Huang ZQ, Jiang HY, Li JY, Liu XP, Zheng YS, Gao FF, et al. Effects of N-n-butly haloperidol iodide on the proliferation of intima and vascular muscle cells of rabbit carotid artery after balloon injury. Chin J Clin Pharmacol Ther. 2012;17:1112–7.
Rechtman MM, Nakaryakov A, Shapira KE, Ehrlich M, Henis YI. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors. J Biol Chem. 2009;284:7843–52.
pubmed: 19147499
pmcid: 2659930
doi: 10.1074/jbc.M809215200
Vaamonde-Garcia C, Malaise O, Charlier E, Deroyer C, Neuville S, Gillet P, et al. 15-Deoxy-Delta-12, 14-prostaglandin J2 acts cooperatively with prednisolone to reduce TGF-beta-induced pro-fibrotic pathways in human osteoarthritis fibroblasts. Biochem Pharmacol. 2019;165:66–78.
pubmed: 30936016
doi: 10.1016/j.bcp.2019.03.039
Fu X, Qie J, Fu Q, Chen J, Jin Y, Ding Z. miR-20a-5p/TGFBR2 axis affects pro-inflammatory macrophages and aggravates liver fibrosis. Front Oncol. 2020;10:107.
pubmed: 32117757
pmcid: 7031347
doi: 10.3389/fonc.2020.00107
Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, et al. ECM1 prevents activation of transforming growth factor beta, hepatic stellate cells, and fibrogenesis in mice. Gastroenterology. 2019;157:1352–67.e13.
pubmed: 31362006
doi: 10.1053/j.gastro.2019.07.036
Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131–6.
pubmed: 11988758
doi: 10.1038/ncb0502-e131
Ryseck RP, Bravo R. c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins. Oncogene. 1991;6:533–42.
pubmed: 1827665
Zhang Z, Gao Z, Hu W, Yin S, Wang C, Zang Y, et al. 3,3’-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol. 2013;170:649–60.
pubmed: 23902531
pmcid: 3792002
doi: 10.1111/bph.12323
Trierweiler C, Hockenjos B, Zatloukal K, Thimme R, Blum HE, Wagner EF, et al. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ. 2016;23:576–82.
pubmed: 26470729
doi: 10.1038/cdd.2015.121
Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, et al. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression. Cell Death Differ. 2019;26:1688–99.
pubmed: 30778201
pmcid: 6748141
doi: 10.1038/s41418-018-0239-8
Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012;143:307–20.
pubmed: 22705006
doi: 10.1053/j.gastro.2012.06.004
Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology. 2010;138:347–59.
pubmed: 19782079
doi: 10.1053/j.gastro.2009.09.015
Mederacke I, Dapito DH, Affo S, Uchinami H, Schwabe RF. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protoc. 2015;10:305–15.
pubmed: 25612230
pmcid: 4681437
doi: 10.1038/nprot.2015.017
Dorn C, Engelmann JC, Saugspier M, Koch A, Hartmann A, Muller M, et al. Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest. 2014;94:394–408.
pubmed: 24492282
doi: 10.1038/labinvest.2014.3
Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res. 2008;68:8173–82.
pubmed: 18829577
pmcid: 2596934
doi: 10.1158/0008-5472.CAN-08-2290
Chen A. Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. Biochem J. 2002;368:683–93.
pubmed: 12223100
pmcid: 1223035
doi: 10.1042/bj20020949
Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33:105–36.
pubmed: 12708612
doi: 10.1080/713611034
Wallace MC, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P, et al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim. 2015;49:21–9.
pubmed: 25835735
doi: 10.1177/0023677215573040
Strnad P, Tao GZ, Zhou Q, Harada M, Toivola DM, Brunt EM, et al. Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology. 2008;134:1169–79.
pubmed: 18395095
doi: 10.1053/j.gastro.2008.01.035
Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.
pubmed: 24264436
doi: 10.1038/ncomms3823
Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54:142–51.
pubmed: 15591520
pmcid: 1774377
doi: 10.1136/gut.2004.042127
Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q, et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem. 1998;273:33750–8.
pubmed: 9837963
doi: 10.1074/jbc.273.50.33750
Zhao Y, Shah DU. Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis. Exp Mol Pathol. 2000;69:67–78.
pubmed: 11001857
doi: 10.1006/exmp.2000.2319
Zhao N, Koenig SN, Trask AJ, Lin CH, Hans CP, Garg V, et al. MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ Res. 2015;116:23–34.
pubmed: 25323858
doi: 10.1161/CIRCRESAHA.115.303970
Jaffe M, Sesti C, Washington IM, Du L, Dronadula N, Chin MT, et al. Transforming growth factor-beta signaling in myogenic cells regulates vascular morphogenesis, differentiation, and matrix synthesis. Arterioscler Thromb Vasc Biol. 2012;32:e1–11.
pubmed: 21979435
doi: 10.1161/ATVBAHA.111.238410
Akhurst RJ, Padgett RW. Matters of context guide future research in TGFbeta superfamily signaling. Sci Signal. 2015;8:re10.
pubmed: 26486175
doi: 10.1126/scisignal.aad0416
Mann J, Mann DA. Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev. 2009;61:497–512.
pubmed: 19393271
doi: 10.1016/j.addr.2009.03.011
Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut. 2002;50:891–6.
pubmed: 12010897
pmcid: 1773234
doi: 10.1136/gut.50.6.891
Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21:4104–13.
pubmed: 12145210
pmcid: 126136
doi: 10.1093/emboj/cdf389
Liu XJ, Yang L, Mao YQ, Wang Q, Huang MH, Wang YP, et al. Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells. World J Gastroenterol. 2002;8:739–45.
pubmed: 12174389
pmcid: 4656331
doi: 10.3748/wjg.v8.i4.739
Fabre T, Kared H, Friedman SL, Shoukry NH. IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-beta receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol. 2014;193:3925–33.
pubmed: 25210118
doi: 10.4049/jimmunol.1400861
Bae HW, Geiser AG, Kim DH, Chung MT, Burmester JK, Sporn MB, et al. Characterization of the promoter region of the human transforming growth factor-beta type II receptor gene. J Biol Chem. 1995;270:29460–8.
pubmed: 7493985
doi: 10.1074/jbc.270.49.29460
Huang Y, Gao F, Zhang Y, Chen Y, Wang B, Zheng Y, et al. N-n-Butyl haloperidol iodide inhibits the augmented Na
pubmed: 22487792
doi: 10.1016/j.bbrc.2012.03.119
Zhou Y, Zhang Y, Gao F, Guo F, Wang J, Cai W, et al. N-n-butyl haloperidol iodide protects cardiac microvascular endothelial cells from hypoxia/reoxygenation injury by down-regulating Egr-1 expression. Cell Physiol Biochem. 2010;26:839–48.
pubmed: 21220915
doi: 10.1159/000323993
Xu D, Wu Y, Liao ZX, Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res. 2007;55:280–6.
pubmed: 17223571
doi: 10.1016/j.phrs.2006.12.003
Hsu YC, Chiu YT, Cheng CC, Wu CF, Lin YL, Huang YT. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroenterol Hepatol. 2007;22:99–111.
pubmed: 17201889
doi: 10.1111/j.1440-1746.2006.04361.x